Sawai Urges Japan To Take 'Best And Only Chance' To Reform Pricing Amid Generic Crisis
Executive Summary
Kenzo Sawai, president of Japanese generics giant Sawai Pharmaceutical, talks about the firm’s strategy and backstory of efforts to maintain product supplies amid the country’s ongoing generic crisis in an exclusive interview. He also urges Japan to take "the best and only chance" to reform its drug pricing system to help the entire market survive.
You may also be interested in...
Nichi-Iko Set To Delist In March As Tamura Steps Down As CEO
After nearly two difficult years for Nichi-Iko Pharmaceutical, the firm has announced at it will be acquired by a private equity fund and delisted from the Toyko Stock Exchange in 2023 and its CEO will step down from his post.
Earnings Recovery For Nichi-Iko Unlikely Before Full Resumption Of Toyama Shipments
Nichi-Iko still has a long road to recovery ahead as it attempts to get its Toyama plant back on its feet.
Nichi-Iko Aims To Regroup As It Enters Turnaround Process
Japan’s Nichi-Iko has formally entered a business turnaround alternative dispute resolution process that will see the company outline a business rehabilitation plan involving management restructuring and a fresh profit structure, following financial underperformance in the wake of recent quality issues.